Libida Cost: What You'll Actually Pay Per Tablet — and What's Not Refundable

Libida cost ranges from $9.97 to $24.90 per tablet across Inner Balance's published plans. The promoted $99.70/month is a monthly equivalent for a plan the provider says bills $299 every three months for 30 tablets. Libida is compounded, requires a prescription, and is excluded from Inner Balance's money-back guarantee.

Best for / not for you if

Libida may be worth considering if you:

• Want an on-demand, needle-free prescription option
• Expect to use it a few times a month rather than automatically consuming ten tablets every month
• Have already had low desire reviewed for medication, medical, pain, and relationship causes
• Can accept that Inner Balance publishes no money-back guarantee for Libida
• Are comfortable confirming the dose, dispensing pharmacy, state availability, and final checkout charge before paying

Libida is probably not your best first purchase if you:

• Need a dose and product-specific evidence you can look up before the consult
• Need a refundable trial
• Are counting on HSA or FSA eligibility without written confirmation
• Have uncontrolled blood pressure, known cardiovascular disease, or another risk that needs clinician review
• Are pregnant
• Have low desire plus pain, dryness, a new medication, depression, thyroid symptoms, or another possible reversible cause that has not been assessed

A licensed clinician has to decide whether any prescription is appropriate for you. This page cannot do that.

The honest answer to the Libida cost question is not "$99.70 a month."

The price can be real and still leave out the part that matters most: what your card is charged, how many tablets arrive, what each tablet costs, and whether any of that money comes back if you stop.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

We are not an Inner Balance affiliate. We earn nothing if you buy Libida. Links to Inner Balance on this page are editorial. We may earn a commission from some other providers mentioned elsewhere on The HRT Index — read our full affiliate disclosure.

What is the Libida cost per tablet on each plan?

Answer: Inner Balance publishes four Libida buying options, but one contains an unresolved contradiction. The clear figures are $249 once for 10 tablets, $199 monthly for 10, and $299 every three months for 30. The two-month offer is listed as $249 for 20 tablets while the same provider page says $279 is charged.

Plan	Provider-published price	Tablets	Billing cadence	Cost per tablet calculated by The HRT Index
One-time order	$249	10	Once	$24.90
Monthly subscription	$199	10	Every month	$19.90
Two-month subscription	$249 listed; same page says $279 charged	20	Every two months	$12.45 at $249; $13.95 at $279
Three-month subscription	$299	30	Every three months	$9.97

Cost-per-tablet figures calculated by The HRT Index from Inner Balance's published prices on August 10, 2026. They are not provider-published unit prices. Sources: Inner Balance's Libida product page and its published pricing article.

Three things fall out of that table.

The "$99.70/month" is a monthly equivalent, not the published charge cadence. Inner Balance lists the three-month option as $299 every three months. $299 ÷ 3 = $99.67, which rounds to $99.70. The provider's terms say two- and three-month prescriptions are collected every two and three months respectively.

The cheapest plan is not the one Inner Balance labels "best value." The provider calls the 20-tablet plan its best-value option on another Libida pricing page. Yet the 30-tablet plan works out to $9.97 per tablet, below either version of the 20-tablet price.

The two-month price cannot be treated as settled. One provider page says "$249 every 2 months for 20 tablets" and then says the same plan is "charged as $279 every 2 months." That is not a rounding issue. Confirm the live charge before choosing it.

The number nobody publishes

The monthly and three-month plans each supply 120 tablets over a full year if renewed on schedule. The annual cash difference is enormous.

Plan	Annual charge	Tablets supplied per year	Calculated cost per tablet
Monthly: $199 × 12	$2,388	120	$19.90
Three-month: $299 × 4	$1,196	120	$9.97

That is $1,192 more for the same published annual tablet count. We could not find that annual comparison on Inner Balance's public pages. It is calculated by The HRT Index from the provider's rates, verified August 2026.

The lower unit rate only saves money if you eventually use the tablets and stop or change the renewal before unwanted inventory builds up. A cheap tablet sitting unused in a drawer is not a saving.

Why does Inner Balance say Libida starts at $99.70 a month?

Answer: The provider's "$99.70/month" headline appears to be the $299 three-month subscription divided by three and rounded. It is useful as a normalized monthly comparison, but it is not the published billing cadence. Inner Balance says the plan is collected every three months, so the decision amount is $299, subject to the live checkout screen.

This distinction sounds pedantic. It is not. It is the reason people search for the price after seeing the ad.

A monthly equivalent helps compare one plan with another. The amount due at checkout determines what you need available and how much is exposed to a no-refund policy.

$299 ÷ 3 = $99.67, displayed as $99.70/month

The Libida product page currently shows "From $99.70/mo" and "20% off." It does not show the plan's tablet count in the visible price block, an undiscounted comparison price, or an expiry date for the promotion.

So do not ask only, "What is the monthly price?" Ask:

What will my card be charged today, how many tablets ship now, and when is the next charge?

That question collapses the ad math into the number that matters.

Can you cancel Libida, and can you get your money back?

Answer: Inner Balance says subscriptions can be canceled through the account portal, but cancellation and refund are separate actions. The current refund policy names Libida among products excluded from the guarantee. Canceling may stop a future renewal; it does not create a right to recover a Libida charge already processed.

Here is the thing worth knowing before you enter a card number.

Libida has no published money-back guarantee.

Inner Balance publishes a six-month guarantee for qualifying Oestra subscription fees and a 30-day guarantee for qualifying face-cream purchases. The same policy expressly places Libida in the "refunds do not apply to" list.

That is a real limitation, and we are not going to soften it.

But it changes the buying logic in a practical way.

Start with the lowest-risk commitment you can verify. The published one-time offer avoids an automatic renewal but costs $249 for 10 tablets. The monthly subscription costs less upfront at $199 for 10, but it renews unless canceled. Decide which risk matters more before chasing the lowest unit price.

If you paid $299 and used 12 of the 30 tablets before stopping, the effective cost of each tablet you actually used would be $24.92.

$299 ÷ 12 used tablets = $24.92 per used tablet

That single decision — start small, then scale only if the fit is real — can be worth more than the discount shown on the product page.

"Cancel anytime" and "refundable" are two different promises

Provider language	What it means in practice
Cancel anytime	You can request that future renewals stop. Inner Balance's terms direct cancellation through the account portal.
Refund	Money already charged is returned. Inner Balance's current policy excludes Libida.
Pharmacy processing	The public terms do not state a Libida-specific cutoff after which an order cannot be stopped. Ask before paying.
Refund request	Cancellation does not automatically submit one. The policy says refund requests must be sent separately through secure chat for products that qualify.

Source: Inner Balance refund policy and terms of use, verified August 10, 2026.

Both FDA-approved HSDD medications also have label-directed stopping rules if symptoms do not improve after eight weeks. That is not a money-back guarantee, but it does create a defined clinical reassessment point in the approved prescribing information.

Does insurance cover Libida? Is it HSA or FSA eligible?

Answer: Inner Balance says it does not accept or bill commercial insurance, Medicare, or Medicaid. HSA and FSA eligibility is unresolved because the Libida product page says "HSA/FSA Eligible," while Inner Balance's dedicated HSA/FSA page says only Oestra is currently eligible. Get a written Libida-specific answer before using health-account funds.

Insurance: no. Inner Balance describes itself as a direct-pay service. Its terms say it does not participate with or bill commercial plans or federal programs and that patients agree not to submit claims. We explain the mechanics on our Inner Balance insurance page.

HSA and FSA: the provider contradicts itself.

Inner Balance source	Current statement
Libida product page	Displays "HSA/FSA Eligible"
Dedicated HSA/FSA page	Says "Currently, only OESTRA is eligible for HSA/FSA payments"
Current refund policy	Says HSA/FSA purchases can be eligible for refunds generally, but separately excludes Libida from refunds

We are not going to pick the convenient side of a provider conflict.

If pre-tax dollars are the reason this feels affordable, do not pay until Inner Balance confirms Libida's eligibility in writing and your plan administrator confirms the expense under your plan. A health-account card processing successfully does not, by itself, settle tax eligibility.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

What's included in the Libida price — and what might cost extra?

Answer: Inner Balance says Libida's price includes the tablets, review of the online assessment by a licensed provider, shipping, a prescription if approved, and unlimited clinical follow-up. Its public terms allow outside tests, services, or prescriptions to create separate costs, and the site does not define the exact format or response time of Libida follow-up.

Provider-stated as included:

• The number of tablets attached to the selected plan
• Licensed-provider review of the online sexual-wellness assessment
• A prescription if the clinician approves treatment
• Shipping
• Ongoing or "unlimited" clinical support

Not resolved on the public Libida pages:

• Whether follow-up means secure messages, live visits, or both
• A guaranteed response time for Libida support
• Whether payment is captured before or after clinical approval
• What happens to the payment if the clinician declines to prescribe
• Whether a clinician could recommend outside testing or another separately billed service
• Whether using a different pharmacy is available for Libida and, if so, what fees remain

Inner Balance's terms say a patient who requests an outside pharmacy may still owe the service's monthly fee while paying the outside pharmacy separately. The terms do not identify Libida as eligible for that arrangement, so treat it as a question—not a promised option.

That is a double-pay door, not an automatic savings route.

Is Libida FDA-approved? Is it equivalent to Vyleesi?

Answer: No. Libida is an individually compounded sublingual prescription product sold by Inner Balance. Vyleesi is an FDA-approved bremelanotide injection with a fixed 1.75 mg dose, approved labeling, product-specific clinical trials, and defined contraindications. Listing bremelanotide in both products does not make their dose, absorption, evidence, quality controls, or clinical use equivalent.

FDA says compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality. FDA also warns telehealth companies against presenting a compounded drug as a generic version of, equivalent to, or FDA-reviewed like an approved product.

Inner Balance does disclose in a product-page footnote that Libida is compounded on an individual basis and that its statements have not been evaluated by FDA. That disclosure matters.

What the public page does not disclose is equally important:

• The amount of bremelanotide in each Libida tablet
• The amount of oxytocin in each tablet
• Product-specific pharmacokinetic or absorption data
• The name and license information of the dispensing pharmacy
• Whether that pharmacy operates for this prescription under section 503A or as a registered 503B outsourcing facility
• A public certificate of analysis supporting the product-page statement that Libida is third-party tested

FDA does not approve or license pharmacies or outsourcing facilities. A provider may truthfully describe a state-licensed pharmacy or an FDA-registered outsourcing facility, but "FDA-approved pharmacy" would be inaccurate.

What the public records do and do not show

Question	Libida	Vyleesi	Addyi
Finished product FDA-approved?	No — compounded	Yes — initial approval 2019	Yes — initial approval 2015
Active ingredients listed publicly	Bremelanotide + oxytocin	Bremelanotide	Flibanserin
Route	Sublingual tablet	Subcutaneous injection	Oral tablet at bedtime
Public dose	Not published	1.75 mg	100 mg
Product-specific FDA prescribing information	No	Yes	Yes
Product-specific peer-reviewed controlled trial found	No	Yes	Yes
FDA-labeled population	No FDA indication	Premenopausal women with acquired, generalized HSDD	Women under 65 with acquired, generalized HSDD
Postmenopausal FDA indication	None	No	Yes, if under 65
Label-directed stop if no improvement	No public product label	After 8 weeks	After 8 weeks

Source: FDA compounding questions and answers, FDA guidance for telehealth promotion of compounded drugs, current Vyleesi prescribing information, and current Addyi prescribing information, verified August 2026.

Libida is the only column without a public dose or product-specific trial. That does not prove it cannot help an individual patient. It means the claims cannot be checked against a published formulation and controlled product-specific evidence.

What's actually in Libida, and how good is the evidence?

Answer: Inner Balance says Libida combines bremelanotide and oxytocin in a sublingual tablet, but it does not publish either dose. We found no peer-reviewed controlled trial of this exact formulation. Controlled evidence exists for bremelanotide injection and intranasal oxytocin separately, but it cannot establish the efficacy, timing, or safety of Libida.

This is where the marketing gets ahead of the public evidence.

Libida's pitch rests on two ideas: bremelanotide for desire and oxytocin for connection. We looked at the controlled evidence for each ingredient in the routes that have actually been studied.

What did the Vyleesi trials find for bremelanotide?

The FDA-approved bremelanotide product was studied in two 24-week placebo-controlled trials in premenopausal women with HSDD. The current label reports:

• Desire score: statistically significant improvement versus placebo
• Distress score: statistically significant improvement versus placebo
• Number of satisfying sexual events: no statistically significant difference from placebo

That third line matters because Inner Balance's Libida page displays "satisfying events per month" as part of a benefit chart. In the controlled trials of the approved bremelanotide injection, the satisfying-event endpoint did not separate from placebo.

The Vyleesi label also says:

• The duration of efficacy after each dose is unknown
• The optimal administration window has not been fully characterized
• Mean terminal half-life is about 2.7 hours

Inner Balance says Libida starts working in 30 to 60 minutes and can last up to 72 hours. That may be a provider-reported observation for a different route and formulation, but no public Libida pharmacokinetic data show how the sublingual product behaves.

The 72-hour claim is not just a clinical claim. It drives the price story. If one tablet reliably covers three days, the cost per use can look low. If the useful window is shorter for a particular patient, the cost per desired occasion rises.

So ask the question the public page does not answer:

What evidence supports the 72-hour duration, and is it specific to the dispensed Libida formulation and dose?

What did controlled studies find for oxytocin?

The most directly relevant controlled study we found was a randomized, double-blind, placebo-controlled crossover trial by Muin and colleagues in 30 women with sexual dysfunction. Participants used 32 IU of intranasal oxytocin or placebo before intercourse, then crossed over.

Both periods improved. Oxytocin did not beat placebo statistically.

Measure	Oxytocin period	Placebo period
Female Sexual Function Index	+26%	+31%
Sexual Quality of Life–Female	+144%	+125%
Sexual Interest and Desire Inventory–Female	+29%	+23%
Female Sexual Distress Scale	−36%	−45%

The authors reported no statistically significant treatment, sequence, or interaction effect.

Two additional controlled studies point in the same cautious direction:

• A 2018 laboratory study in healthy women found no significant effect of intranasal oxytocin on subjective or objective sexual measures.
• A 2014 couples study reported some changes in orgasm intensity and post-sex contentment but did not establish a broad improvement across standard desire and arousal measures.

All three studies used intranasal oxytocin, not an undisclosed-dose sublingual combination. They cannot prove that Libida does not work. They do show that a compelling "bonding hormone" explanation is not the same thing as a demonstrated product effect.

Sources: Muin et al., 2015, Kruger et al., 2018, and Behnia et al., 2014.

What about Inner Balance's "over 10,000 women" results?

Inner Balance reports internal outcomes from more than 10,000 women and says more than half felt more mentally interested in intimacy within 60 minutes. The public page does not provide:

• A protocol or registration
• The exact formulation and dose evaluated
• A comparator group
• Eligibility criteria
• Completion and dropout numbers
• Adverse-event tables
• Statistical methods
• A peer-reviewed publication

We are not saying the internal numbers are invented. We are saying they are provider-reported outcomes, not independently established controlled evidence. With placebo improvements this large in the oxytocin trial, a comparison group is exactly what would make the internal results interpretable.

Does Libida work for menopausal women?

Answer: Inner Balance markets Libida to premenopausal, perimenopausal, surgically menopausal, and postmenopausal women. No peer-reviewed trial of the specific product was found. Vyleesi's FDA label limits bremelanotide injection to premenopausal women, while Addyi's label expanded in December 2025 to women under 65 regardless of reproductive status.

This is the finding most likely to change the decision for a postmenopausal reader.

The Vyleesi label says it is not indicated for HSDD in postmenopausal women. Its phase 3 population was premenopausal.

That does not automatically transfer to an undisclosed-dose compounded sublingual combination. It also does not provide evidence for Libida in postmenopause. It leaves the product-specific question unanswered.

Meanwhile, FDA approved an expanded Addyi indication in December 2025. The current label covers women under 65 with acquired, generalized HSDD and includes data from a 24-week randomized placebo-controlled trial in naturally postmenopausal women.

In that trial:

• 447 women received Addyi and 455 received placebo
• Mean age was 55
• Satisfying sexual events increased by 0.9 per 28 days with Addyi and 0.6 with placebo
• The adjusted treatment difference was 0.4 events per 28 days
• Desire and distress measures also favored Addyi

The trial excluded women with significant comorbidities including uncontrolled hypertension, uncontrolled diabetes, cardiovascular disease, uncorrected thyroid disorders, and psychiatric disorders. Its results do not describe every postmenopausal woman who may be considering treatment.

The effect is not magic. Addyi is a daily bedtime pill, carries a boxed warning about severe low blood pressure and fainting in specified settings, is contraindicated with moderate or strong CYP3A4 inhibitors and in liver impairment, and must be stopped after eight weeks if there is no improvement.

But for a postmenopausal woman under 65, it is now an FDA-approved option with a public dose, label, trial, and stopping rule. That deserves a place in the decision.

What should be ruled out before buying a libido prescription?

Both FDA labels define HSDD as low desire that causes distress and is not explained by another medical or psychiatric condition, relationship problems, or a medication or drug.

That definition exists because several common problems can look like "my libido disappeared" while needing a different first step:

• An SSRI or another medication associated with sexual side effects
• Pain during sex, dryness, or genitourinary syndrome of menopause
• Thyroid disease
• Depression, anxiety, exhaustion, or sustained stress
• Relationship distress
• Another medical condition

If pain, dryness, medication effects, or another treatable cause is driving the problem, no libido tablet at any price is the right first purchase.

This is where we would rather lose the click than help you spend $299 on the wrong target.

Does that sound like your situation? Use Find My HRT Path to separate a libido-treatment question from a broader menopause-care question and to flag when online care is not the right starting point.

How does Libida's cost compare with Vyleesi and Addyi?

Answer: Libida can have the lowest allocated cost per on-demand use, but only on its larger plans and only if every purchased tablet is eventually used. Addyi's current manufacturer cash price is $149 per month through PhilRx. Vyleesi's official program lists $99 for a four-dose box when insurance does not cover it.

The first mistake is comparing a recurring daily medication with two products priced by on-demand dose.

The second is multiplying a per-tablet number by expected uses while ignoring the actual renewal. A subscription can charge on schedule even when tablets are accumulating.

Published cash price and commitment

Option	Public cash price	Quantity / dosing frame	What is charged	Key limit
Libida one-time	$249	10 tablets	$249 once	$24.90 per tablet
Libida monthly	$199	10 tablets	$199 every month	$19.90 per tablet
Libida three-month	$299	30 tablets	$299 every three months	$9.97 per tablet
Addyi through PhilRx	$149	One month of daily treatment	$149 each month	Prescription and eligibility required
Vyleesi without coverage through BlinkRx	$99	Four single-dose autoinjectors	$99 per box	Label says no more than 8 doses per month

The Addyi site currently contains two commercial-insurance promotional figures: its main access page says "as little as $20/month," while its FAQ says "as little as $40 per year." Both say eligibility restrictions apply. Because those figures are not available to everyone and the official pages disagree on presentation, this comparison uses the clear $149 monthly cash price, not the lowest promotional outcome.

Vyleesi's official site says most eligible commercially insured patients may pay as little as $0 for a four-dose box and that patients without coverage can obtain a four-dose box for $99. Government-funded program restrictions and other eligibility terms apply.

What does expected use do to the math?

The table below is an allocation model, not a prediction of what a subscription will charge. It assumes every purchased Libida or Vyleesi dose is eventually used and that you cancel the Libida subscription before a renewal would create more inventory than you need.

Expected uses per month	Libida 30-tablet plan: allocated monthly cost	How long 30 tablets last	Libida 10-tablet monthly plan: allocated monthly cost	Vyleesi at $99 / 4 doses	Addyi cash price
2	$19.93	15 months	$39.80	$49.50	$149
4	$39.87	7.5 months	$79.60	$99.00	$149
8	$79.73	3.75 months	$159.20	$198.00	$149
10	$99.67	3 months	$199.00	Above Vyleesi label's recommended monthly maximum	$149

What that table says, plainly:

• At low use, the 30-tablet Libida plan has the lowest allocated cost per used dose—but it still requires a $299 commitment and will renew every three months unless changed.
• At two or four uses a month, a 30-tablet shipment would last far beyond the three-month billing cycle. Without a timely change, the subscription can create inventory faster than you use it.
• At ten uses a month, the three-month Libida plan normalizes to $99.67 monthly; the monthly Libida plan is $199; Addyi's cash price is $149.
• Vyleesi is labeled for no more than eight doses per month and is not indicated for postmenopausal women.
• Addyi is taken daily, so "cost per experience" is not a label-based way to price it.

The lowest mathematical rate is not automatically the best purchase. The right comparison is:

Cash due now + renewal timing + doses you will actually use + refund exposure + whether the formulation fits your clinical situation.

Who is Libida a reasonable buy for — and who should skip it?

Answer: Libida is a defensible cash-pay choice for a woman who wants an on-demand, needle-free prescription, expects modest use, has ruled out reversible causes, and accepts the missing public dose and no-refund policy. It is a poor fit when transparent formulation, FDA-reviewed evidence, insurance coverage, or a refundable commitment is the priority.

Your priority	Best next move
Lowest published Libida unit price	Confirm the $299 charge, 30-tablet quantity, renewal date, and cancellation cutoff before paying
Smallest published nonrenewing Libida commitment	Confirm the one-time $249 / 10-tablet offer is available at checkout; the monthly plan is $50 less upfront but renews
A dose and label you can look up	Discuss an FDA-approved option with a prescriber
A money-back trial	Do not assume Libida offers one; its published policy excludes it
Commercial insurance support	Check Addyi and Vyleesi coverage before assuming cash-pay compounding is cheaper
HSA/FSA funds	Get Libida-specific eligibility in writing because Inner Balance's pages conflict
Known cardiovascular disease or uncontrolled blood pressure	Pause the purchase and review the risk with a clinician
Low desire plus pain or dryness	Assess genitourinary symptoms rather than treating this as desire alone
Low desire after starting a medication	Ask whether the medication could be contributing
Age 65 or older	Neither Addyi's current indication nor Vyleesi's indication answers this automatically; use a clinician who can assess the cause and options
Need the exact dispensing pharmacy	Ask before checkout; the public Libida page does not name it
State-specific access	Confirm availability during intake; Inner Balance's terms say services can vary by location

Why are we not padding this section with a list of other compounded libido products?

Because this page's core finding is that dose, formulation, pharmacy, and price should be checkable. Sending you sideways to another opaque compounded offer would not resolve the objection. It would just move it.

What are the safety limits that affect the buying decision?

Answer: Inner Balance lists nausea, flushing, headache, temporary blood-pressure elevation, and pigmentation among Libida concerns, but no product-specific controlled safety table is public. Vyleesi's FDA label provides controlled bremelanotide data, including 40% nausea and cardiovascular and pigmentation warnings, but those rates cannot be assigned directly to a different compounded route and dose.

We are not going to call Libida safe or say its side effects are mild. The public evidence does not support that blanket statement.

Here is what can be said accurately.

In Vyleesi's placebo-controlled trials, nausea was reported in 40% of treated patients versus 1% on placebo. That is a Vyleesi rate—not a Libida rate—but it is materially different from marketing language that makes bremelanotide side effects sound uniformly mild.

The cardiovascular wording does not match

Inner Balance says Libida should not be used with uncontrolled blood pressure, untreated heart disease, or during pregnancy.

Vyleesi's label contraindicates use in uncontrolled hypertension or known cardiovascular disease and says it is not recommended for patients at high cardiovascular risk.

"Untreated" and "known" are not the same threshold.

That does not prove the Vyleesi contraindication legally or clinically applies unchanged to an undisclosed-dose compounded sublingual product. It does mean a person with treated heart disease should not assume Inner Balance's narrower website wording settles the risk.

The pigmentation framing is materially different

Inner Balance says about 1% may develop pigmentation, associates it with high-frequency dosing, calls it cosmetic, and says it often fades.

The Vyleesi label says focal hyperpigmentation occurred in 1% of patients using up to eight doses per month—within labeled use. In another study, 38% developed pigmentation after eight consecutive daily doses, with an additional 14% after another eight days. The label says resolution was not confirmed in all patients.

Again, these are Vyleesi data, not Libida incidence rates. They are the controlled public safety data for bremelanotide, and they do not support dismissing pigmentation as always temporary.

The published Libida dosing limit is more restrictive

Inner Balance directs users not to take more than one tablet in 72 hours. Vyleesi's label allows no more than one dose in 24 hours and recommends no more than eight doses per month.

That is a genuine difference in the provider's stated frequency limit. Without Libida's dose and pharmacokinetic data, we cannot tell what drove it.

What should you confirm before paying for Libida?

Answer: Confirm the exact charge, tablet count, renewal date, cancellation cutoff, ingredient doses, dispensing pharmacy, state availability, HSA/FSA status, and what happens if the clinician declines treatment. Inner Balance's public pages answer some of these incompletely and contradict one another on the two-month price and health-account eligibility.

Save the answers. Screenshot the checkout screen before you submit payment.

What remains unresolved	Ask this exact question
Amount charged today	"What exact amount will be charged today—not the monthly equivalent?"
Tablet count and renewal	"How many tablets ship now, and on what date will the next charge occur?"
Two-month contradiction	"Is the 20-tablet plan $249 or $279 every two months?"
20% promotion	"Is the quoted plan price before or after the 20% offer, what is the regular comparison price, and when does the offer end?"
Ingredient doses	"How many milligrams of bremelanotide and how much oxytocin are in each tablet?"
Dispensing pharmacy	"Which pharmacy fills my prescription, in which state is it licensed, and is it operating as a 503A pharmacy or 503B outsourcing facility for this order?"
Testing claim	"Can you provide the product-specific certificate of analysis or explain what third-party testing covers?"
HSA/FSA conflict	"Your Libida page says HSA/FSA eligible, while your HSA/FSA page says only Oestra is eligible. Which applies to my purchase?"
Cancellation cutoff	"What is the final date and time to cancel before the next charge and before pharmacy processing?"
Clinician decline	"If the clinician does not approve treatment, what amount is refunded and on what timeline?"
State availability	"Is Libida available to be prescribed and dispensed to my current state?"
Follow-up access	"Does unlimited clinical follow-up include a live clinician visit, secure messages, or both, and what response time should I expect?"

Do not rely on a verbal summary for the money questions. Keep the written response with the checkout screenshot. The point is not to create a dispute file. The point is to prevent one.

What do customers say about Libida's price and billing?

Answer: Independent Libida-specific review volume is very small and cannot establish efficacy or typical experience. One current Trustpilot review independently reports receiving 30 tablets for about $300 and being denied a prescription refund, which aligns with the published plan and Libida exclusion. Other Inner Balance reviews describe both successful and frustrating refund interactions for different products.

A March 2026 Trustpilot reviewer wrote:

"A three month supply is 30 pills, not 90… now I'm out $300."

That is one person's report, not proof of medical effectiveness or a typical outcome. It is useful only for the commercial detail: the reviewer describes the same 30-tablet / roughly $300 commitment shown in Inner Balance's published pricing and says the order was not refunded.

For balance, an Oestra reviewer wrote that the refund "wasn't a hassle." Oestra is covered by a published guarantee; Libida is not. A smooth Oestra refund does not change Libida's terms.

As of August 10, 2026:

• Trustpilot displays 15 reviews on the profile linked to www.innerbalance.com, with a 3.1 TrustScore. The volume is too small to treat the score as stable or representative.
• BBB lists Inner Balance Health PLLC as not accredited, with a B− rating and 12 complaints. BBB says it does not verify third-party allegations or endorse businesses.

Billing, cancellation, and support appear repeatedly in the small public review set. Treat those reports as signals for what to document—not as adjudicated facts.

Sources: Trustpilot profile for www.innerbalance.com and BBB business profile, checked August 10, 2026.

What did The HRT Index actually verify?

Answer: We applied The HRT Index Verification Standard: read Inner Balance's current product, pricing, refund, HSA/FSA, and terms pages; separated provider claims from FDA-reviewed facts; checked current Vyleesi and Addyi labeling; reviewed relevant oxytocin studies; and reproduced every unit, annual, and use-frequency calculation shown here.

We verified

• The product page displays "From $99.70/mo," 20% off, HSA/FSA eligibility, free shipping, and unlimited follow-up
• Inner Balance publishes $249 / 10, $199 / 10, $249 or $279 / 20, and $299 / 30 plan figures
• The provider's terms state that two- and three-month prescriptions are collected every two and three months
• The refund policy specifically excludes Libida
• Inner Balance does not bill insurance
• The HSA/FSA pages conflict
• The exact Libida dose and dispensing pharmacy are not named publicly
• Libida is disclosed as compounded
• Vyleesi is not indicated for postmenopausal women
• Addyi's indication changed in December 2025 to women under 65
• The Vyleesi trials did not show a significant difference in satisfying sexual events
• The cited intranasal oxytocin studies do not establish efficacy for Libida
• The current official Addyi and Vyleesi cash-access prices used in this page

We did not do

• Buy Libida
• Complete the medical intake
• Reach the final personalized checkout screen
• Receive or inspect a dispensed label
• Verify a product-specific certificate of analysis
• Test the medication
• Confirm a Libida prescription in every state

We could not confirm publicly

• Milligrams of bremelanotide per tablet
• Oxytocin dose per tablet
• Product-specific absorption and duration data
• Dispensing pharmacy identity
• 503A or 503B status for the dispensed prescription
• Whether the headline price is before or after the displayed 20% promotion
• The true current two-month charge
• Libida-specific HSA/FSA eligibility
• A Libida-specific cancellation cutoff
• Payment handling after a clinician declines to prescribe
• State-by-state availability
• What "unlimited clinical follow-up" includes

The HRT Index Verification Standard evaluates providers on five things, in this order:

1. Clinical legitimacy — prescriber model, dispensing source, regulatory category, and evidence
2. Care quality — intake, clinician access, follow-up, and continuity
3. Medication fit — route, formulation, FDA-approved versus compounded status, dose transparency, and studied population
4. Price transparency — charge, cadence, quantity, unit cost, annual cost, and refund exposure
5. Access — state availability, insurance, HSA/FSA, shipping, and cancellation

Who created this page: The HRT Index Editorial Team.

How: Primary-source commercial verification, FDA label review, peer-reviewed literature review, and reproducible arithmetic shown on the page.

Why: Because the irreversible part of this decision—the charge—can happen before the public website tells you the dose or resolves its own pricing and HSA/FSA conflicts.

This page has not been reviewed by a clinician. That is stated plainly because readers deserve to know which work is editorial and which has clinical review.

Found a price or policy that changed? Send us the source and a screenshot so we can re-check it and update the verification date.

Frequently asked questions

How much does Libida cost per month?

Inner Balance publishes a $199 monthly subscription for 10 tablets. The lower "$99.70/month" headline is the $299 three-month plan divided by three and rounded. The provider says the three-month plan is collected every three months, so $99.70 is a monthly equivalent, not the published billing cadence.

How many Libida tablets do you get?

Inner Balance's current pricing article lists 10 tablets for the $249 one-time order, 10 for the $199 monthly plan, 20 for the two-month plan, and 30 for the $299 three-month plan. The Libida product-page price block does not show the count, so confirm it on the final checkout screen.

How much does Libida cost per tablet?

The calculated range is $9.97 to $24.90 per tablet. The $299 / 30-tablet plan is $9.97 each. The $249 / 10-tablet one-time order is $24.90 each. The unresolved two-month plan is $12.45 per tablet at $249 or $13.95 at the same page's stated $279 charge.

Is $99.70 what Inner Balance will charge today?

The public three-month plan says $299 is collected every three months. The $99.70 figure appears to be that amount divided by three. Confirm the final amount due today before submitting payment because The HRT Index did not complete a personalized checkout.

Is Libida covered by insurance?

Inner Balance says it does not accept or bill commercial insurance, Medicare, or Medicaid. Its terms also say patients agree not to submit claims. Medication coverage through a separate route is not established for Libida because the public page does not identify the dispensing pharmacy or outside-pharmacy process for this product.

Can I use an HSA or FSA card for Libida?

Do not treat it as confirmed. The Libida product page says HSA/FSA eligible, while Inner Balance's dedicated HSA/FSA page says only Oestra is currently eligible. Ask Inner Balance for a Libida-specific written answer and confirm the expense with your plan administrator.

Can I get a refund on Libida?

Inner Balance's current refund policy specifically excludes Libida. Canceling a subscription can stop future renewals, but cancellation does not make a Libida purchase refundable.

How do I cancel Libida?

Inner Balance's terms direct customers to cancel through the account portal. Ask for written confirmation and the exact cutoff relative to the next billing date and pharmacy processing. The public terms do not publish a Libida-specific cutoff.

Is Libida FDA-approved?

No. Inner Balance discloses that Libida is compounded on an individual basis. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality.

Is Libida equivalent to Vyleesi?

No. Libida is a sublingual compounded combination with an unpublished dose. Vyleesi is an FDA-approved 1.75 mg subcutaneous bremelanotide injection with product-specific labeling and controlled trials. The presence of bremelanotide in both does not establish equivalent dose, absorption, effect, quality controls, or safety.

Does Libida work if I am postmenopausal?

Inner Balance says it prescribes Libida to postmenopausal women, but no peer-reviewed trial of the exact product was found. Vyleesi is not indicated for postmenopausal women. Addyi is FDA-approved for women under 65, including postmenopausal women, and has a public postmenopausal trial in its current label.

Can I take Libida with HRT?

Inner Balance calls Libida non-hormonal and says it can be used with or without HRT. Whether the combination is appropriate depends on your health history and medications and must be decided by the prescribing clinician. The public page does not publish a product-specific interaction study for Libida.

What is the Libida dose?

Inner Balance instructs patients to dissolve one tablet under the tongue 30 to 60 minutes before intimacy and not to exceed one tablet per 72 hours. The public page does not disclose the amount of bremelanotide or oxytocin in that tablet.

Is there a Libida discount code?

The product page currently displays "20% off" without a visible expiry date or undiscounted comparison price. Do not calculate savings from that badge alone. Confirm whether the plan price shown at checkout already includes the promotion and save the checkout screen.

Does Libida ship to every state?

The public Libida page does not publish a state list. Inner Balance's terms say some services may not be available in all locations. Confirm that a licensed clinician can prescribe and the pharmacy can dispense to your state before paying.

The bottom line

If you want an on-demand option without a needle, expect to use it modestly, and can accept a compounded product with no public dose and no money-back guarantee, Libida can be a defensible purchase.

But buy the decision you can verify—not the monthly-equivalent headline.

Confirm the charge. Confirm the tablet count. Confirm the dose and pharmacy. Choose the lowest-risk commitment—not merely the lowest unit price. Scale only after you know the prescription fits your situation and you are willing to keep it.

If you need a public dose, FDA-reviewed labeling, a postmenopausal indication, or insurance support, there are real alternatives worth discussing before you put $299 at risk.

Either way, do not let a "from" price make the decision for you.

Still not sure which HRT program is right for you? Take our free 60-second matching quiz.

Find My HRT Path →

---

Educational content only. This is not medical advice and is not a substitute for care from a licensed clinician who knows your history. Pricing, policies, and product information were verified in August 2026 and can change.